Skip to content
MARKETS / BALCAO / ADMT
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

ADM Tronics Unlimited, Inc. ADMT

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.3M
▲ 4.7% YoY
$-100,374
In brief

What this company does

The Company is a technology-based developer and manufacturer of diversified lines of products and derives revenue from the production and sale of electronics for medical devices and other applications; environmentally safe chemical products for industrial, medical and cosmetic uses; and, research, development, regulatory and engineering services. The Company is a corporation organized under the laws of the State of Delaware on November 24, 1969. We develop and manufacture electronic technologies for non-invasive, electrotherapeutic and diagnostic medical devices as well as for veterinary and other applications. The Company derives revenues from contract manufacturing of electronic medical and other devices from non-affiliated customers. We develop, manufacture, and sell chemical products to industrial users. Through its Antistatic Industries division, the Company develops, manufactures, and distributes conductive and antistatic products for commercial and industrial applications. We believe that our present insurance coverage is adequate for the types of products we currently market.

Written from the business description in ADM Tronics Unlimited, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 10 July 2026. Every sentence was checked against that document before publication.

Growth
USD 3.3M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 3.3 · Net income -0.1
2.0M4.0M-0.5M-1.0M201020122014201620182020202220242025
Compound annual growth
−3.1%
+1.6%
−2.9%
+7.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +1.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−3 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -4.8% · Net -3.0%
10%20%-20%-40%201020122014201620182020202220242025
ROE
FY2025 · ROE -16.2%
100%200%-100%-200%201020122014201620182020202220242025

Each USD of equity lost 16 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks

Total assetsUSD 1.8M
EquityUSD 570,972.00
CashUSD 255,730.00
Current ratio0.98×

Equity funds 31% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.00.00.00.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.00.0−0.0−0.00.0−0.0−0.00.00.00.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.0−0.00.00.0−0.0−0.0····−0.0·
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.00.0−0.0−0.0−0.0−0.0
Free cash flow $B··············0.0·
EPS, diluted $0.000.00···−0.010.00−0.010.000.020.020.010.00−0.010.00−0.01
Dividend / sh $················
Payout %················
ROE %−16.2−18.0−77.7−6.6−67.0−19.6−2.8−9.52.940.082.6215.2−257.6−132.9−3.7−93.9
Shares out B0.070.070.070.070.070.070.070.070.070.070.070.060.060.060.060.06

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 73 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 22 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inDelaware
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image